Cargando…
Data Submission Standards and Evidence Requirements
Presented are recommendations of the Data Submission Standards and Evidence Requirements panel from the Conference on Clinical Cancer Research along with the U.S. Food and Drug Administration's response to these recommendations.
Autores principales: | Abrams, Jeffrey, Erwin, Robert, Fyfe, Gwen, Schilsky, Richard L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227973/ https://www.ncbi.nlm.nih.gov/pubmed/20489185 http://dx.doi.org/10.1634/theoncologist.2009-0260 |
Ejemplares similares
-
Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer
por: Schilsky, Richard L., et al.
Publicado: (2010) -
Waiting for JAK inhibitor safety data
por: Kragstrup, Tue Wenzel, et al.
Publicado: (2022) -
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020) -
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
por: Toussirot, Eric, et al.
Publicado: (2017) -
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)